Polyphase wireless power transfer system achieves 270-kilowatt charge, s...
Kathy McCarthy, associate laboratory director for Fusion and Fission Energy and Science at the Department of Energy’s Oak Ridge National Laboratory, has been elected fellow of the American Nuclear Society for her nationally and internationally recognized leadership in nuclear energy and fusion.
An ORNL-led team comprising researchers from multiple DOE national laboratories is using artificial intelligence and computational screening techniques – in combination with experimental validation – to identify and design five promising drug therapy approaches to target the SARS-CoV-2 virus.
Oak Ridge National Laboratory expertise in fission and fusion has come together to form a new collaboration, the Fusion Energy Reactor Models Integrator, or FERMI
Belinda Akpa is a chemical engineer with a talent for tackling big challenges and fostering inclusivity and diversity in the next generation of scientists.
Toward the goal of bringing the next generation of nuclear power reactor technology online this decade, ORNL and Analysis and Measurement Services Corporation have successfully completed loop testing of instrument and control sensors for an advanced reactor design for small modular reactors.
The U.S. Department of Energy’s Innovative and Novel Computational Impact on Theory and Experiment, or INCITE, program is seeking proposals for high-impact, computationally intensive research campaigns in a broad array of science, engineering and computer science domains.
Rich Giannone uses bioanalytical mass spectrometry to examine proteins, the primary driver in biological systems.
The Accelerating Therapeutics for Opportunities in Medicine , or ATOM, consortium today announced the U.S. Department of Energy’s Oak Ridge, Argonne and Brookhaven national laboratories are joining the consortium to further develop ATOM’s artificial intelligence, or AI-driven, drug discovery platform.
A rare isotope in high demand for treating cancer is now more available to pharmaceutical companies developing and testing new drugs.
Scientists have found new, unexpected behaviors when SARS-CoV-2 – the virus that causes COVID-19 – encounters drugs known as inhibitors, which bind to certain components of the virus and block its ability to reproduce.